Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,164,591

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

GILD vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ILMN: Which Stock Is the Better Value Option?

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) has been gaining investor confidence on robust performance.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall

by Zacks Equity Research

Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?

by Zacks Equity Research

Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Sweta Jaiswal, FRM headshot

Biotechnology Market on a Tear: 5 ETFs in Spotlight

by Sweta Jaiswal, FRM

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Sweta Jaiswal, FRM headshot

Global X Launches GNOM ETF to Tap Booming Genomics Space

by Sweta Jaiswal, FRM

Having exposure to trending areas like Robotics & AI, e-commerce and IoT, Global X is set to gain from the booming genomics market with the GNOM ETF.

Medtronic's New Data for HVAD System to Boost CRHF Segment

by Zacks Equity Research

Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.

Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake

by Zacks Equity Research

The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.

Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm

by Zacks Equity Research

The recent development will help Bio-Rad (BIO) rake in increased top-line contributions from the Clinical Diagnostics business.

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina (ILMN) is currently keeping well with its goals to strengthen foothold in the multi-billion gene sequencing market.

Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Illumina (ILMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Illumina (ILMN) closed at $309.84, marking a +0.21% move from the previous day.

LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Align Technology-Benco Dental Deal to Expand iTero Reach

by Zacks Equity Research

Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

GNC Holdings to Expand Portfolio With Alani Nutrition Deal

by Zacks Equity Research

With Alani Nutrition being a women-focused supplement brand, it is believed that the partnership might help GNC Holdings (GNC) widen its customer base.

Tandem's Global Growth a Boost, Operating Losses a Bane

by Zacks Equity Research

Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.

GNC Forms Joint Venture With IVC to Improve Cost Efficiency

by Zacks Equity Research

The joint venture is set to manufacture the products produced by GNC Holdings' (GNC) Nutra manufacturing facility.

Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.